Novozymes A/S Increases Expectations For Full-Year Profit After Strong Q3
The first nine months of 2014 delivered a sales increase of 8%.
COPENHAGEN, DENMARK – October 23, 2014 - Novozymes, the world’s largest producer of industrial enzymes, today announced its 2014 third quarter results. Organic sales increased by 8% compared with the first nine months 2013. EBIT grew by 16%, and the EBIT margin was 27.4%, when compared with the first nine months of 2013. Approximately half of the EBIT margin is due to the one-time positive impact from The BioAg Alliance, and the other half due to improved underlying earnings. As a result, expectations for full-year EBIT growth, EBIT margin, net profit growth, ROIC and free cash flow have increased.
“We continue to see a good development in our business nine months into the year, and we increase the outlook for profit and cash flow for the full year,” says Novozymes’ CEO Peder Holk Nielsen. “Innovation has been a key driver of top and bottom line, and recent currency developments are contributing positively to the outlook. Sales have been in line with expectations, and we narrow in the outlook for organic sales growth to the middle of the range. Uncertainties remain in a number of markets and in the macro environment, but our strong and diversified portfolio is broadly positioned for growth, and that is expected to prove valuable yet again.”
Novozymes’ executive leadership team will present the results at a conference call today at 12.00 pm CET: http://www.novozymes.com/en/investor/events-presentations/Pages/conference-call.aspx The entire earnings report can be downloaded at news.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
MEDIA CONTACTS
Europe
Frederik Bjørndal
Mobile: +44 (0) 7976 138 265
tfbh@novozymes.com
Denmark
René Tronborg
Office: +45 44462274
Mobile: +45 30772274
retr@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
China
Lian Meng
Office: +86 106 298 7888+392
Mobile: +86 136 992 31164
mexl@novozymes.com
Brazil
Henrique Pellini
Office: +55 41 36411000
Mobile: +55 41 9288-0282
hqp@novozymes.com
India
Kanak Angirish
Mobile: +91 8030593500
kna@novozymes.com
INVESTOR CONTACTS
Europe
Thomas Steenbech Bomhoff
Office: +45 4446 1226
Mobile: +45 3077 1226
tsbm@novozymes.com
US
Martin Riise
Office: +1 919 494 3483
Mobile: +1 919 649 2565
mrsn@novozymes.com
Help employers find you! Check out all the jobs and post your resume.
COPENHAGEN, DENMARK – October 23, 2014 - Novozymes, the world’s largest producer of industrial enzymes, today announced its 2014 third quarter results. Organic sales increased by 8% compared with the first nine months 2013. EBIT grew by 16%, and the EBIT margin was 27.4%, when compared with the first nine months of 2013. Approximately half of the EBIT margin is due to the one-time positive impact from The BioAg Alliance, and the other half due to improved underlying earnings. As a result, expectations for full-year EBIT growth, EBIT margin, net profit growth, ROIC and free cash flow have increased.
“We continue to see a good development in our business nine months into the year, and we increase the outlook for profit and cash flow for the full year,” says Novozymes’ CEO Peder Holk Nielsen. “Innovation has been a key driver of top and bottom line, and recent currency developments are contributing positively to the outlook. Sales have been in line with expectations, and we narrow in the outlook for organic sales growth to the middle of the range. Uncertainties remain in a number of markets and in the macro environment, but our strong and diversified portfolio is broadly positioned for growth, and that is expected to prove valuable yet again.”
Novozymes’ executive leadership team will present the results at a conference call today at 12.00 pm CET: http://www.novozymes.com/en/investor/events-presentations/Pages/conference-call.aspx The entire earnings report can be downloaded at news.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
MEDIA CONTACTS
Europe
Frederik Bjørndal
Mobile: +44 (0) 7976 138 265
tfbh@novozymes.com
Denmark
René Tronborg
Office: +45 44462274
Mobile: +45 30772274
retr@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
China
Lian Meng
Office: +86 106 298 7888+392
Mobile: +86 136 992 31164
mexl@novozymes.com
Brazil
Henrique Pellini
Office: +55 41 36411000
Mobile: +55 41 9288-0282
hqp@novozymes.com
India
Kanak Angirish
Mobile: +91 8030593500
kna@novozymes.com
INVESTOR CONTACTS
Europe
Thomas Steenbech Bomhoff
Office: +45 4446 1226
Mobile: +45 3077 1226
tsbm@novozymes.com
US
Martin Riise
Office: +1 919 494 3483
Mobile: +1 919 649 2565
mrsn@novozymes.com
Help employers find you! Check out all the jobs and post your resume.